EyePoint, Inc. announced the completion of enrollment in two pivotal Phase 3 clinical trials, COMO and CAPRI, evaluating DURAVYU™ (vorolanib intravitreal insert) for diabetic macular edema (DME). The company enrolled over 480 participants across both global trials within five months, ahead of schedule. Topline data from these DME studies is anticipated in the fourth quarter of 2027. This milestone follows a Data Safety Monitoring Committee review that recommended continuing both the DME and wet AMD Phase 3 programs without protocol modifications. EyePoint, Inc. operates as a clinical-stage biopharmaceutical company developing innovative therapeutics for serious retinal diseases.

EyePoint, Inc. entered into a settlement agreement with the U.S. Department of Justice and other agencies to settle potential civil False Claims Act violations related to DEXYCU sales and marketing practices between 2019 and 2023. The company will pay a settlement amount of $4,678,981.86 plus 4.25% interest, along with $166,500 in attorney's fees. Additionally, the company entered into a five-year Corporate Integrity Agreement with OIG-HHS to maintain compliance oversight. EyePoint, Inc. is a pharmaceutical company that commercializes healthcare products.

At its 2026 Annual Meeting of Stockholders on June 18, 2026, EyePoint, Inc. stockholders approved an amendment to the 2023 Long-Term Incentive Plan, increasing the number of authorized common shares for issuance by 4,900,000. Stockholders also elected eight directors, ratified the appointment of Deloitte & Touche LLP as the independent auditor for fiscal year 2026, and approved named executive officer compensation on a non-binding advisory basis. The company operates in the biotechnology industry and develops ophthalmic pharmaceuticals.